Pros | - | ![]() Among most bought funds within the category. ![]() Larger AUM within category. ![]() Beats FD returns for both 3Y & 5Y duration. | ||
Cons | - | ![]() 5Y returns in the bottom 25% of the category. |
INDMoney rank | - | 6/8 | ||
Category,Subcateogry | Equity,Sector - Healthcare | Equity,Sector - Healthcare | ||
Fund Age | 3 Years | 12 Years | ||
Fund Size | 230 Cr | 8569 Cr | ||
Min Investment | SIP ₹500 Lumpsum ₹5000 | SIP ₹100 Lumpsum ₹5000 | ||
Expense Ratio | 0.47% | 0.89% | ||
Exit Load | 0.5% | 1% | ||
Benchmark Index | Nifty Healthcare TR INR | BSE Healthcare TR INR |
No of Holdings | 40 | 40 | ||
Top 5 Holdings | Sun Pharmaceuticals Industries Ltd (15.18%) Divi's Laboratories Ltd (9.12%) Max Healthcare Institute Ltd Ordinary Shares (5.42%) Lupin Ltd (5.4%) Apollo Hospitals Enterprise Ltd (5.19%) | Sun Pharmaceuticals Industries Ltd (12.57%) Divi's Laboratories Ltd (9.49%) Lupin Ltd (5.82%) Cipla Ltd (5.62%) Dr Reddy's Laboratories Ltd (5.49%) | ||
No of Sectors | 3 | 1 | ||
Top 3 Sectors | Health (95.43%) Basic Materials (3.64%) Industrial (0.93%) | Health (100%) | ||
Equity % | 99.71% | 98.58% | ||
Debt % | - | - | ||
P/E | 40.95 | 37.82 | ||
P/B | 6.07 | 6.01 | ||
Credit Quality | - | - | ||
Modified Duration | - | - | ||
YTM | - | - |
1-Month Return | 0.73% | 0.28% | ||
3-Month Return | 8.35% | 9.74% | ||
6-Month Return | -1.03% | 1.26% | ||
1-Year Return | 13.87% | 12.81% | ||
3-Year Return | 24.96% | 25.53% | ||
5-Year Return | - | 23.06% |
Sharpe | 1.19 | 1.26 | ||
Alpha | 2.56 | 1.03 | ||
Beta | 0.9 | 0.9 | ||
Standard Deviation | 15.46 | 14.76 | ||
Information Ratio | 0.26 | -0.25 |
Description | ITI Pharma and Healthcare Fund Direct Growth is an equity fund.The fund could potentially beat inflation in the long-run. | Nippon India Pharma Fund - Direct Plan - Growth Plan is an equity fund.The fund could potentially beat inflation in the long-run. | ||
Managers | - | Kinjal Desai,Sailesh Raj Bhan |